Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

about

Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

Item

http://www.wikidata.org/entity/Q42701083

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

@en

Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

@nl

type

Item

label

Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

@en

Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

@nl

prefLabel

Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

@en

Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

@nl

P1476

Cardiovascular safety of celecoxib on top of dual antiplatelet therapy.

@en

P2093

Bum-Kee Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study

Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers

Selective COX-2 inhibition improves endothelial function in coronary artery disease

Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling

Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

P304

306-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.4070/KCJ.2010.40.7.306

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45389675

http://www.w3.org/2001/XMLSchema#string

P698

20664737

http://www.w3.org/2001/XMLSchema#string

P932

2910285

http://www.w3.org/2001/XMLSchema#string